Current Report Filing (8-k)
June 13 2018 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
June 13, 2018
PROTAGENIC
THERAPEUTICS, INC.
(Exact
name of Company as specified in its charter)
Delaware
|
|
000-51353
|
|
06-1390025
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
149
Fifth Avenue, Suite 500, New York, NY
|
|
10010
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
212-994-8200
(Company’s
telephone number, including area code)
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD.
On
June 13, 2018, Protagenic Therapeutics, Inc. (the “Company”) issued a letter to its stockholders reporting on the
Company’s developmental progress toward filing an FDA Investigational New Drug (IND) application for its three targeted
clinical indications. The stockholder letter, as well as the cover page to the Company’s annual report, are furnished as
Exhibit 99.1 hereto.
The
information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by referenced in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific referenced in such a filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
|
|
Date:
June 13, 2018
|
By:
|
/s/
Alexander K. Arrow
|
|
Name:
|
Alexander
K. Arrow, MD
|
|
Title:
|
Chief
Financial Officer
|